[Clinical experiences with the new antidepressive agent ICI 58,834].
In an open study 17 patients with depressive disorders, 5 patients with unipolar affec. Only 9 patients completed the trial. The frequency of side-effects, especially nausea and vomiting was high, which will probably limit the clinical use of the drug. Of the sion NUD, were treated with a new potential antidepressant, ICI 58.834 (Vivalan). tive psychosis, 9 patients with reactio-neurotico-depressiva and 3 patients with deprespatients who completed the trial 1 was recovered and 4 were improved. Thus the antidepressive effect is dubious and must be tested in controlled studies.